You are here

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Last updated on November 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Berkely, California, 94704 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Carcinoma
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically confirmed breast cancer with metastases

- Tumor that has overexpression of HER2 as documented by being either FISH-positive or
HER2/neu 3+ confirmed by immunohistochemistry

- Patients may have had up to three prior chemotherapy regimens for metastatic disease,
which may have been given in combination with Herceptin® and which may have been
discontinued due to toxicities. In addition, patients may have had adjuvant
chemotherapy.

- Phase II only: Must have measurable disease by RECIST criteria (defined in section 8)
with at least one lesion that can be accurately measured in at least one dimension
(longest diameter to be recorded) as > 20 mm with conventional techniques, or as > 10
mm with spiral CT scan

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any prior therapy with anthracycline + Herceptin® concurrently

- Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure,
myocardial infarction within the past 6 months, unstable angina; coronary angioplasty
within the past 6 months, uncontrolled atrial or ventricular cardiac arrhythmias) or
left ventricular ejection fraction

- Pre-existing autoimmune or antibody-mediated diseases including but not limited to:
systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's
syndrome, autoimmune thrombocytopenia

NCT00043394
Pfizer
Completed
CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
Official Title  ICMJE A Phase I/II Open Label, Multi-Center, Dose-Escalation Study Of Subcutaneous CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
Brief SummaryTo determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Carcinoma, Breast
Intervention  ICMJE
  • Drug: 0.04 mg/kg CpG 7909
    0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
    Other Name: PF-03512676, ProMune
  • Drug: Herceptin®
    Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
    Other Name: Trastuzumab
  • Drug: 0.08 mg/kg CpG 7909
    0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
    Other Name: PF-03512676, ProMune
  • Drug: 0.12 mg/kg CpG 7909
    0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
    Other Name: PF-03512676, ProMune
  • Drug: 0.16 mg/kg CpG 7909
    0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
    Other Name: PF-03512676, ProMune
Study Arms  ICMJE
  • Experimental: Cohort 1
    0.04 mg/kg CpG 7909
    Interventions:
    • Drug: 0.04 mg/kg CpG 7909
    • Drug: Herceptin®
  • Experimental: Cohort 2
    0.08 mg/kg CpG 7909
    Interventions:
    • Drug: 0.08 mg/kg CpG 7909
    • Drug: Herceptin®
  • Experimental: Cohort 3
    0.12 mg/kg CpG 7909 Injection once weekly
    Interventions:
    • Drug: 0.12 mg/kg CpG 7909
    • Drug: Herceptin®
  • Experimental: Cohort 4
    0.16 mg/kg CpG 7909
    Interventions:
    • Drug: 0.16 mg/kg CpG 7909
    • Drug: Herceptin®
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 11, 2009)
16
Original Enrollment  ICMJE
 (submitted: June 23, 2005)
64
Actual Study Completion Date  ICMJE October 2003
Actual Primary Completion DateOctober 2003   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically confirmed breast cancer with metastases
  • Tumor that has overexpression of HER2 as documented by being either FISH-positive or HER2/neu 3+ confirmed by immunohistochemistry
  • Patients may have had up to three prior chemotherapy regimens for metastatic disease, which may have been given in combination with Herceptin® and which may have been discontinued due to toxicities. In addition, patients may have had adjuvant chemotherapy.
  • Phase II only: Must have measurable disease by RECIST criteria (defined in section 8) with at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques, or as > 10 mm with spiral CT scan

Exclusion Criteria:

  • Any prior therapy with anthracycline + Herceptin® concurrently
  • Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure, myocardial infarction within the past 6 months, unstable angina; coronary angioplasty within the past 6 months, uncontrolled atrial or ventricular cardiac arrhythmias) or left ventricular ejection fraction < 50%
  • Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00043394
Other Study ID Numbers  ICMJE C015
A8501021, CO15
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyDirector, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateMarch 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now